Prelude Therapeutics Incorporated
PRLD · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Assets | – | – | – | – |
| Cash & Equivalents | $48 | $26 | $40 | $12 |
| Short-Term Investments | $7 | $47 | $59 | $121 |
| Receivables | $0 | $0 | $0 | $0 |
| Inventory | $0 | $0 | $0 | $0 |
| Other Curr. Assets | $3 | $4 | $3 | $2 |
| Total Curr. Assets | $58 | $77 | $102 | $136 |
| Property Plant & Equip (Net) | $33 | $34 | $35 | $35 |
| Goodwill | $0 | $0 | $0 | $0 |
| Intangibles | $0 | $0 | $0 | $0 |
| Long-Term Investments | $3 | $0 | $0 | $0 |
| Tax Assets | $0 | $0 | $0 | $0 |
| Other NC Assets | $0 | $4 | $4 | $4 |
| Total NC Assets | $36 | $38 | $39 | $40 |
| Other Assets | $0 | $0 | $0 | $0 |
| Total Assets | $95 | $115 | $141 | $176 |
| Liabilities | – | – | – | – |
| Payables | $3 | $5 | $6 | $8 |
| Short-Term Debt | $3 | $3 | $3 | $3 |
| Tax Payable | $0 | $0 | $0 | $0 |
| Deferred Revenue | $0 | $0 | $0 | $0 |
| Other Curr. Liab. | $13 | $13 | $11 | $15 |
| Total Curr. Liab. | $18 | $21 | $20 | $26 |
| LT Debt | $15 | $15 | $15 | $15 |
| Deferred Rev, NC | $0 | $0 | $0 | $0 |
| Deferred Tax Liab, NC | $0 | $0 | $0 | $0 |
| Other NC Liab. | $3 | $3 | $3 | $3 |
| Total NC Liab. | $18 | $18 | $18 | $18 |
| Other Liabilities | $0 | $0 | $0 | $0 |
| Cap. Leases | $15 | $18 | $18 | $18 |
| Total Liabilities | $36 | $39 | $38 | $44 |
| Equity | – | – | – | – |
| Pref Stock | $0 | $0 | $0 | $0 |
| Common Stock | $0 | $0 | $0 | $0 |
| Retained Earnings | -$667 | -$647 | -$616 | -$584 |
| AOCI | $0 | -$0 | $0 | $0 |
| Other Equity | $725 | $723 | $719 | $715 |
| Total Equity | $59 | $76 | $103 | $131 |
| Supplemental Information | – | – | – | – |
| Minority Interest | $0 | $0 | $0 | $0 |
| Total Liab. & Tot. Equity | $95 | $115 | $141 | $176 |
| Net Debt | -$30 | -$8 | -$22 | $6 |